What is the recommended management for a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap?

Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Overlap

Immediately discontinue the culprit drug and transfer the patient to a burn center or ICU with SJS/TEN experience for multidisciplinary supportive care, as this is the cornerstone of management that directly impacts mortality. 1

Immediate Actions Upon Diagnosis

Drug Withdrawal

• Stop all potential causative drugs immediately - this is the single most critical intervention affecting survival 1
• Review all medications from the previous 2 months, including over-the-counter and complementary therapies
• Most culprit drugs have a latency period of 5-28 days from initiation to symptom onset 1

Prognostic Assessment

Calculate SCORTEN within the first 24 hours to predict mortality risk 1. This score guides intensity of care and family counseling.

Care Setting and Team Structure

Patients with SJS/TEN overlap (10-30% BSA epidermal detachment) require immediate admission to a burn center or ICU with the following capabilities 1:

• Barrier nursing in a side room with controlled humidity
• Pressure-relieving mattress
• Ambient temperature maintained at 25-28°C
• Multidisciplinary team coordinated by dermatology/plastic surgery, including:
  • Intensive care specialists
  • Ophthalmology (mandatory - ocular involvement occurs early)
  • Specialist skincare nursing
  • Microbiology, pain team, dietetics, physiotherapy

Critical pitfall: Delayed transfer to specialized centers is associated with increased mortality 1. Transfer should occur without delay once diagnosis is suspected.

Supportive Care Protocol

Skin Management

Conservative approach (first-line for all patients) 1:

• Gentle cleansing: Irrigate with warmed sterile water, saline, or chlorhexidine (1:5000)
• Emollient application: Apply 50% white soft paraffin with 50% liquid paraffin over entire epidermis, including denuded areas
• Blister management: Decompress blisters by piercing; leave detached epidermis in situ as biological dressing
• Dressing protocol:
  • Apply nonadherent dressings (Mepitel™ or Telfa™) to denuded dermis
  • Use secondary foam/burn dressing to collect exudate (Exu-Dry™)
• Topical antimicrobials: Apply to sloughy areas only (consider silver-containing products, but limit use if extensive areas involved due to absorption risk)

Infection surveillance 1:

• Take bacterial and candidal swabs from three lesional areas on alternate days
• Do NOT use prophylactic systemic antibiotics - this increases Candida colonization
• Administer antibiotics only when clinical signs of infection present (confusion, hypotension, reduced urine output, oxygen desaturation, increased skin pain, rising CRP, neutrophilia)

Surgical Approach

Consider transfer to burn center for surgical intervention if 1:

• Clinical deterioration
• Extension of epidermal detachment
• Subepidermal pus or local sepsis
• Wound conversion (progression to deeper defect)
• Delayed healing

Surgical protocol includes:

• Debridement of necrotic/infected epidermis under general anesthesia
• Wound cleansing with betadine or chlorhexidine
• Physiological closure with Biobrane/allograft/xenograft for noninfected confluent areas

Fluid Management

Fluid requirements are LOWER than burn formulas predict 1:

• Avoid overaggressive resuscitation (causes pulmonary, cutaneous, intestinal edema)
• Formula: body weight (kg) × % BSA epidermal detachment = mL required
• Site IV lines through nonlesional skin when possible; change peripheral lines every 48 hours
• Monitor urine output carefully; catheterize if urogenital involvement causes dysuria/retention
• Transition to oral fluids as mouth involvement improves

Nutrition

Continuous enteral nutrition throughout acute phase 1:

• Early catabolic phase: 20-25 kcal/kg/day
• Anabolic recovery phase: 25-30 kcal/kg/day
• Insert nasogastric tube if patient cannot maintain adequate oral intake

Pain Management

• Use validated pain assessment tools daily
• Provide adequate baseline analgesia for comfort at rest
• Supplement with opiates as needed for procedural pain 1

Specific Pharmacologic Interventions

The evidence for immunomodulatory therapy remains controversial. Recent research suggests:

For SJS/TEN overlap specifically 2:

• Combination of IVIG + corticosteroids appears most effective based on recent systematic reviews
• Cyclosporine may have positive prognostic effects when initiated early 3, 2

However, the 2016 UK Guidelines prioritize supportive care and do not make definitive recommendations for specific immunomodulatory agents, emphasizing that optimal therapy remains debated [1-1].

Critical Monitoring

Ocular Care

• Early ophthalmology consultation is mandatory
• Purulent keratoconjunctivitis and eyelid involvement occur early 1
• Long-term ocular sequelae are among the most common complications 3

Respiratory and GI Surveillance

• Monitor for cough, dyspnea, bronchial hypersecretion, hemoptysis 1
• Assess for diarrhea and abdominal distension 1

Mucosal Sites

• Examine eyes, mouth, nose, genitalia for mucositis, blisters, erosions 1
• Watch for HSV reactivation in slow-healing eroded areas, particularly genital and oral sites 1

Key Pitfalls to Avoid

1. Delayed drug withdrawal - every hour counts
2. Prophylactic antibiotics - increases fungal colonization without benefit
3. Overaggressive fluid resuscitation - use lower volumes than burn formulas
4. Inadequate ophthalmology involvement - ocular complications are permanent
5. Shearing forces during handling - use antishear techniques when moving patients
6. Missing HSV reactivation - consider in non-healing erosions

The mortality rate for SJS/TEN overlap (10-30% BSA involvement) ranges from 12-32% based on SCORTEN parameters 1. Early recognition, immediate drug cessation, and prompt transfer to specialized care are the interventions with the strongest evidence for reducing mortality.